Abbvie demonstrates 96% SVR(12) in its phase III study of treatment-experienced patients with genotype 1 hepatitis C - MARG
December 10, 2013
Abbvie demonstrates 96% SVR(12) in its phase III study of treatment-experienced patients with genotype 1 hepatitis C